Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

News in brief

S&P downgrades inVentiv after Q1 results miss expectations


Standard & Poor's has downgraded inVentiv Health’s credit rating after the CRO posted weaker than expected first quarter results.

In April S&P gave inVentiv a ‘fair’ business risk profile but readjusted this down to ‘weak’ in the wake of disappointing first quarter results. Cash flow was below expectations and S&P fears synergies from the acquisitions of i3, PharmaNet, and other businesses are at least another year away.

First-quarter results were weaker than expected, even after accounting for a previously announced project delay that hurt the Clinical segment. This leads us to believe inVentiv will increase business and expand margins at a significantly slower pace than previously expected”, S&P wrote.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Key Industry Events


Access all events listing

Our events, Events from partners...